Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review

A. Kaplan (Toronto, Canada), J. Fitzgerald (Vancouver, Canada), G. El Azzi (Ingelheim am Rhein, Germany), M. Engel (Ingelheim am Rhein, Germany), R. Buhl (Mainz, Germany)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1033
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Kaplan (Toronto, Canada), J. Fitzgerald (Vancouver, Canada), G. El Azzi (Ingelheim am Rhein, Germany), M. Engel (Ingelheim am Rhein, Germany), R. Buhl (Mainz, Germany). Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review. 1033

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: